Suyash Prasad

Summary

Publications

  1. ncbi A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
  2. ncbi The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
  3. ncbi Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
  4. ncbi Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
  5. ncbi Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005

Collaborators

  • David Coghill
  • Michael Tettenborn
  • Joanne Barton
  • Chelvi Kukendra
  • Chunnaiah Yemula
  • Baljinder Singh
  • Mohan Chandola
  • Kanagasabai Puvanendran
  • Avninder Spencer
  • Somnath Banerjee
  • Nikos Myttas
  • Valerie Harpin
  • Saroj Jamdar
  • Geetha Kugan
  • Senerath Perera
  • Ian Male
  • John Dearlove
  • Nigel Speight
  • Christopher Steer
  • Arthur Speight
  • Anne McClure
  • Chris Steer
  • Jorge Arellano
  • Louise Timlin
  • Karina Hart
  • Stephen Ralston
  • Duncan Manders
  • Sarah Jenkins
  • Joanne Parker
  • Lynne Poole
  • Patricia Mooney

Detail Information

Publications5

  1. ncbi A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD)
    Suyash Prasad
    Dept Neurosciences, Eli Lilly and Co Ltd, Basingstoke, UK
    Curr Med Res Opin 23:379-94. 2007
    ....
  2. ncbi The provision and nature of ADHD services for children/adolescents in the UK: results from a nationwide survey
    Michael Tettenborn
    Frimley Children s Centre, UK
    Clin Child Psychol Psychiatry 13:287-304. 2008
    ..Results of the survey provide an important insight into the ADHD-related services provided by ADORE centres, as well as highlighting the availability and limitations of such services...
  3. ncbi Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence
    Suyash Prasad
    Department of Paediatrics, Cromwell Hospital, London, UK
    Paediatr Drugs 10:39-47. 2008
    ..We conclude that patients with ADHD can be switched from neurostimulants, specifically methylphenidate, to atomoxetine, and may benefit from symptom improvement...
  4. ncbi Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK
    S Prasad
    Department Paediatrics, Cromwell Hospital, London, UK
    Int J Clin Pract 63:1031-40. 2009
    ..For attention-deficit/hyperactivity disorder (ADHD), economic evaluations have largely focused on pharmacotherapy, and results indicate that such treatments are cost-effective compared with other interventions...
  5. ncbi Atomoxetine hydrochloride and executive function in children with attention-deficit/hyperactivity disorder
    Joanne Barton
    J Child Adolesc Psychopharmacol 15:147-9. 2005